BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ruggeri M, Basile M, Coretti S, Drago C, Cicchetti A. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy. Appl Health Econ Health Policy 2017;15:479-90. [DOI: 10.1007/s40258-017-0311-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Cochrane Hepato-Biliary Group, Jing Wu, Shitong Xie, Yanfang Ma, Xiaoning He, Xinyue Dong, Qianling Shi, Qiangqiang Guo, Qi Wang, Meixuan Li, Naijuan Yao, Liang Yao. Entecavir for children and adults with chronic hepatitis B. Cochrane Database Syst Rev 2023;2023:CD015536. [ DOI: 10.1002/14651858.CD015536] [Reference Citation Analysis]
2 Memirie ST, Desalegn H, Naizgi M, Nigus M, Taddesse L, Tadesse Y, Tessema F, Zelalem M, Girma T. Introduction of birth dose of hepatitis B virus vaccine to the immunization program in Ethiopia: an economic evaluation. Cost Eff Resour Alloc 2020;18:23. [PMID: 32704237 DOI: 10.1186/s12962-020-00219-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
3 Ruggeri M, Romano F, Basile M, Coretti S, Rolli FR, Drago C, Cicchetti A. Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy. Appl Health Econ Health Policy. 2018;16:711-722. [PMID: 30039348 DOI: 10.1007/s40258-018-0410-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
4 Wigfield P, Sbarigia U, Hashim M, Vincken T, Heeg B. Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review. Pharmacoecon Open 2020;4:403-18. [PMID: 31428938 DOI: 10.1007/s41669-019-00175-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Matza LS, Boye KS, Jordan JB, Norrbacka K, Gentilella R, Tiebout AR, Browne C, Orsini Federici M, Biricolti G, Stewart KD. Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. Patient Prefer Adherence 2018;12:971-9. [PMID: 29922043 DOI: 10.2147/PPA.S159620] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ruggeri M, Basile M, Drago C, Rolli FR, Cicchetti A. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy. PharmacoEconomics 2018;36:625-36. [DOI: 10.1007/s40273-018-0643-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Roberts-Thomson IC, Lung T. Cost-effective options for the prevention and management of gastrointestinal and liver disease in the Asia-Pacific region. J Gastroenterol Hepatol 2018;33:121-7. [PMID: 28833619 DOI: 10.1111/jgh.13925] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Tenofovir most cost effective for chronic hepatitis B in Italy. PharmacoEcon Outcomes News 2017;772:34-34. [DOI: 10.1007/s40274-017-3782-5] [Reference Citation Analysis]